Thiazolidinediones and cardiovascular outcomes in type 2 diabetes

被引：6
|
作者：
Singh, Sonal [1 ]
Furberg, Curt D. [2 ]
机构：
[1] Wake Forest Univ, Sch Med, Gen Internal Med Sect, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA
来源：
HEART | 2009年 / 95卷 / 01期
关键词：
ROSIGLITAZONE; PIOGLITAZONE; MELLITUS; RISK; METAANALYSIS; EVENTS; ASSOCIATION; PREVENTION; STATEMENT; THERAPY;
D O I：
10.1136/hrt.2008.155507
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 50 条
  • [21] Thiazolidinediones in type 2 diabetes: A cardiology perspective
    Khanderia, Ujjaini
    Pop-Busui, Rodica
    Eagle, Kim A.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (10) : 1466 - 1474
  • [22] Thiazolidinediones for initial treatment of type 2 diabetes?
    Nathan, David M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23): : 2477 - 2480
  • [23] Thiazolidinediones and blood lipids in type 2 diabetes
    van Wijk, JPH
    de Koning, EJP
    Martens, EP
    Rabelink, TJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) : 1744 - 1749
  • [24] Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Chiu, Lu-Ting
    Hsu, Chih-Cheng
    Hou, Ming-Chih
    Hwu, Chii-Min
    LIVER INTERNATIONAL, 2021, 41 (01) : 110 - 122
  • [25] Attenuating cardiovascular disease risk factors in patients with type 2 diabetes with metformin, sulfonylureas, and thiazolidinediones
    Buse, J
    Harmel, AP
    Kendall, D
    Boyle, P
    Marchetti, A
    Lau, H
    DIABETES, 2003, 52 : A443 - A443
  • [26] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Buse, John B.
    Engel, Samuel S.
    Garg, Jyotsna
    Josse, Robert
    Kaufman, Keith D.
    Koglin, Joerg
    Korn, Scott
    Lachin, John M.
    McGuire, Darren K.
    Pencina, Michael J.
    Standl, Eberhard
    Stein, Peter P.
    Suryawanshi, Shailaja
    Van de Werf, Frans
    Peterson, Eric D.
    Holman, Rury R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03): : 232 - 242
  • [27] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Reply
    Buse, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1798 - +
  • [28] Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
    Gerstein, Hertzel C.
    Sattar, Naveed
    Rosenstock, Julio
    Ramasundarahettige, Chinthanie
    Pratley, Richard
    Lopes, Renato D.
    Lam, Carolyn S. P.
    Khurmi, Nardev S.
    Heenan, Laura
    Del Prato, Stefano
    Dyal, Leanne
    Branch, Kelley
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10): : 896 - 907
  • [29] SAXAGLIPTIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES
    Raz, I
    Scirica, B. M.
    Braunwald, E.
    Mosenzon, O.
    Hirshberg, B.
    Wiviott, S. D.
    Frederich, R.
    Davidson, J.
    Leiter, L. A.
    Bhatt, D. L.
    HYPERTENSION, 2014, 63 (06) : E167 - E167
  • [30] Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
    Ganda, Om P.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2016, 83 : S11 - S17
12345